Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Current Leases (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Current Leases data on record, last reported at $29865.0 in Q3 2025.

  • For Q3 2025, Current Leases rose 201.97% year-over-year to $29865.0; the TTM value through Sep 2025 reached $29865.0, up 201.97%, while the annual FY2024 figure was $42305.0, 11.19% up from the prior year.
  • Current Leases reached $29865.0 in Q3 2025 per COEP's latest filing, up from $21738.0 in the prior quarter.
  • Across five years, Current Leases topped out at $42305.0 in Q1 2024 and bottomed at $9890.0 in Q3 2024.
  • Average Current Leases over 5 years is $27372.1, with a median of $29865.0 recorded in 2025.
  • The widest YoY moves for Current Leases: up 201.97% in 2025, down 23.91% in 2025.
  • A 5-year view of Current Leases shows it stood at $14724.0 in 2021, then skyrocketed by 182.65% to $41618.0 in 2022, then decreased by 8.58% to $38047.0 in 2023, then rose by 11.19% to $42305.0 in 2024, then fell by 29.41% to $29865.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $29865.0 in Q3 2025, $21738.0 in Q2 2025, and $32191.0 in Q1 2025.